Details for Patent: 6,043,230
✉ Email this page to a colleague
Title: | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Abstract: | Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure -OC(R.sup.2).sub.2 OC(O) X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, axido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally. |
Inventor(s): | Arimilli; Murty N. (Fremont, CA), Cundy; Kenneth C. (Belmont, CA), Dougherty; Joseph P. (New York, NY), Kim; Choung U. (San Carlos, CA), Oliyai; Reza (San Ramon, CA), Stella; Valentino J. (Lawrence, KS) |
Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
Filing Date: | May 19, 1999 |
Application Number: | 09/314,606 |
Claims: | 1. A method comprising contacting a cell with a compound of formula (1a) ##STR33## wherein Z is independently --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, an ester, an amidate or --H, but at least one Z is --OC(R.sup.2).sub.2 OC(O)X(R).sub.a ; A is the residue of an antiviral phosphonomethoxy nucleotide analog; X is N or O; R.sup.2 independently is --H, C.sub.1 -C.sub.12 alkyl, C.sub.5 -C.sub.12 aryl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, C.sub.7 -C.sub.12 alkenylaryl, C.sub.7 -C.sub.12 alkynylaryl, or C.sub.6 -C.sub.12 alkaryl, any one of which is unsubstituted or is substituted with 1 or 2 halo, cyano, azido, nitro or --OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl or C.sub.5 -C.sub.12 aryl; R independently is --H, C.sub.1 -C.sub.12 alkyl, C.sub.5 -C.sub.12 aryl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, C.sub.7 -C.sub.12 alkyenylaryl, C.sub.7 -C.sub.12 alkynylaryl, or C.sub.6 -C.sub.12 alkaryl, any one of which is unsubstituted or is substituted with 1 or 2 halo, cyano, azido, nitro, --N(R.sup.4).sub.2 or --OR.sup.3, where R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 when X is O, or 1 or 2 when X is N; with the proviso that when a 2 and X is N, (a) two N-linked R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, (b) one N-linked R additionally can be --OR.sup.3 or (c) both N-linked R groups can be --H. |